Similar articles

• Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia.

  Inokuchi K, Yamaguchi H, Tamai H, Dan K. Inokuchi K, et al. J Clin Exp Hematop. 2012;52(2):145-7. doi: 10.3960/jslrt.52.145. J Clin Exp Hematop. 2012. PMID: 23037633 No abstract available.
• Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.

  Erba HP, Pham DC, Zaiden R, Vu H, Tai S. Erba HP, et al. Clin Adv Hematol Oncol. 2011 Oct;9(10):734-45. Clin Adv Hematol Oncol. 2011. PMID: 22252576 Review.
• 10 years of progress in chronic myelogenous leukemia.

  Jabbour E, Mathisen MS, O'Brien S. Jabbour E, et al. J Natl Compr Canc Netw. 2012 Sep;10(9):1049-53. doi: 10.6004/jnccn.2012.0110. J Natl Compr Canc Netw. 2012. PMID: 22956803 No abstract available.
• Two new agents effective in Gleevec-resistant CML.

  [No authors listed] [No authors listed] Cancer Biol Ther. 2004 Dec;3(12):1198-9. Cancer Biol Ther. 2004. PMID: 15864854 No abstract available.
• [State of the art in the treatment of chronic leukemias].

  Ohnishi K. Ohnishi K. Rinsho Ketsueki. 2006 Apr;47(4):278-86. Rinsho Ketsueki. 2006. PMID: 16715962 Review. Japanese. No abstract available.